In our recent Experts Knowledge Share, world-renowned experts discussed case studies, reviewed the latest data and shared their views.
Guest expert Prof. Fred Saad joined GU CONNECT members Assoc. Prof Tanya Dorff, Prof. Gerhardt Attard, and Prof. Neeraj Agarwal, along with participants from around the world, to discuss incorporating PARP inhibitors into prostate cancer clinical practice.
GU CONNECT invites you to watch the video replay, download the accompanying slides, and take the e-learning using the blue button below the video to claim your CME credit.
Incorporating PARP inhibitors into prostate cancer clinical practice.
Chapter 1 00:00 Scene-setting - Prof. Fred Saad
Chapter 2 05:23 Use of PARP inhibitors beyond the first-line setting in mCRPC - Prof. Fred Saad and Prof. Gerhardt Attard
Chapter 3 39:24 Use of PARP inhibitors in the first-line setting in mCRPC - Assoc. Prof. Tanya Dorff and Prof. Neeraj Agarwal
Chapter 4 1:09:50 Questions and panel discussion
Chapter 5 1:14:06 Future perspectives and summary - Prof. Fred Saad
PARP inhibitors are an important part of the treatment strategy for mCRPC patients
mCRPC patients who harbour HRR mutations benefit from PARPi monotherapy following progression on prior novel hormonal agents
Treatment with PARP inhibitors plus novel hormonal agents can provide combination benefits in mCRPC patients with or without HRR mutations
The future treatment landscape for prostate cancer patients will likely include the earlier introduction of PARPi's and treatment beyond patients with HRR/DRR mutations